Accidental Once-Daily Use of Dulaglutide: A Case Report.
作者信息
Moore Hannah E, Zaya Viva, Burns Carly V, Berlie Helen D
机构信息
Corewell Health, William Beaumont University Hospital, Royal Oak, MI.
Pharmacy Advantage Specialty Pharmacy-Henry Ford Health, Rochester Hills, MI.
出版信息
Clin Diabetes. 2024 Summer;42(3):454-457. doi: 10.2337/cd23-0035. Epub 2024 Jan 12.
Abstract
摘要
相似文献
1
Accidental Once-Daily Use of Dulaglutide: A Case Report.度拉糖肽意外每日一次使用：一例报告
Clin Diabetes. 2024 Summer;42(3):454-457. doi: 10.2337/cd23-0035. Epub 2024 Jan 12.
2
Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.每周一次度拉鲁肽对比每日一次利拉鲁肽治疗二甲双胍控制不佳的 2 型糖尿病患者（AWARD-6）：一项随机、开放标签、3 期、非劣效性试验。
Lancet. 2014 Oct 11;384(9951):1349-57. doi: 10.1016/S0140-6736(14)60976-4. Epub 2014 Jul 10.
3
Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study.对于日本2型糖尿病患者，每周一次的胰高血糖素样肽-1受体激动剂度拉糖肽不劣于每日一次的利拉鲁肽且优于安慰剂：一项为期26周的随机III期研究。
Diabetes Obes Metab. 2015 Oct;17(10):974-83. doi: 10.1111/dom.12534. Epub 2015 Aug 20.
4
Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once-daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study.在日本2型糖尿病患者中，与每日一次的利拉鲁肽相比，每周一次的胰高血糖素样肽-1受体激动剂度拉糖肽可显著降低糖化血红蛋白：一项随机III期研究中的52周治疗。
Diabetes Obes Metab. 2016 Mar;18(3):249-57. doi: 10.1111/dom.12602. Epub 2016 Jan 8.
5
Switching From Daily DPP-4 Inhibitor to Once-Weekly GLP-1 Receptor Activator Dulaglutide Significantly Ameliorates Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes Mellitus: A Retrospective Observational Study.从每日 DPP-4 抑制剂转换为每周一次 GLP-1 受体激动剂度拉糖肽可显著改善血糖控制不佳的 2 型糖尿病患者的血糖控制：一项回顾性观察研究。
Front Endocrinol (Lausanne). 2021 Aug 6;12:714447. doi: 10.3389/fendo.2021.714447. eCollection 2021.
6
Efficacy and safety of once-weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open-label, phase III, non-inferiority study.与一日一次甘精胰岛素相比，一周一次度拉糖肽联合磺脲类药物和/或双胍类药物治疗日本2型糖尿病患者的疗效和安全性：一项随机、开放标签、III期、非劣效性研究
Diabetes Obes Metab. 2015 Oct;17(10):994-1002. doi: 10.1111/dom.12540. Epub 2015 Aug 20.
7
Network meta-analysis accurately predicted the outcome of a subsequent randomised trial comparing once weekly dulaglutide 1.5 mg and once daily liraglutide 1.8 mg.网状荟萃分析准确预测了随后一项比较每周一次度拉糖肽1.5毫克和每日一次利拉鲁肽1.8毫克的随机试验的结果。
Int J Clin Pract. 2016 Mar;70(3):218-21. doi: 10.1111/ijcp.12775. Epub 2016 Feb 24.
8
Dulaglutide: A Review in Type 2 Diabetes.度拉糖肽：用于 2 型糖尿病的治疗。
BioDrugs. 2015 Dec;29(6):407-18. doi: 10.1007/s40259-015-0143-4.
9
Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide.接受胰高血糖素样肽-1 受体激动剂治疗的 2 型糖尿病患者的治疗模式：与每周一次的艾塞那肽和利拉鲁肽相比，度拉糖肽具有更高的依从性和持久性。
Diabetes Obes Metab. 2017 Jul;19(7):953-961. doi: 10.1111/dom.12902. Epub 2017 Mar 16.
10
Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting.在西班牙背景下，评估每周一次司美格鲁肽与度拉鲁肽和西他列汀的长期成本效益。
Adv Ther. 2020 Oct;37(10):4427-4445. doi: 10.1007/s12325-020-01464-1. Epub 2020 Aug 29.
本文引用的文献
1
Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice.管理肥胖症中 GLP-1 受体激动剂的胃肠道副作用：临床实践建议。
Postgrad Med. 2022 Jan;134(1):14-19. doi: 10.1080/00325481.2021.2002616. Epub 2021 Nov 29.
2
GLP-1 receptor agonists: an updated review of head-to-head clinical studies.胰高血糖素样肽-1受体激动剂：头对头临床研究的最新综述
Ther Adv Endocrinol Metab. 2021 Mar 9;12:2042018821997320. doi: 10.1177/2042018821997320. eCollection 2021.
3
Liraglutide toxicity presenting to the emergency department: A case report and literature review.利拉鲁肽中毒在急诊科的表现：一例病例报告及文献综述。
Emerg Med Australas. 2019 Oct;31(5):895-896. doi: 10.1111/1742-6723.13343. Epub 2019 Jul 15.
4
A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin.一项为期 26 周的随机对照试验，比较了每日一次司美格鲁肽与利拉鲁肽和安慰剂在饮食和运动控制不佳的 2 型糖尿病患者中的疗效，这些患者在加用或不加用二甲双胍的情况下。
Diabetes Care. 2018 Sep;41(9):1926-1937. doi: 10.2337/dc17-2381. Epub 2018 Jul 19.
5
Clinical Pharmacokinetics of Dulaglutide in Patients with Type 2 Diabetes: Analyses of Data from Clinical Trials.度拉糖肽在2型糖尿病患者中的临床药代动力学：来自临床试验数据的分析
Clin Pharmacokinet. 2016 May;55(5):625-34. doi: 10.1007/s40262-015-0338-3.
6
Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study.每周一次度拉鲁肽对比睡前胰岛素甘精，均联合餐时胰岛素赖脯氨酸，用于治疗 2 型糖尿病患者（AWARD-4）：一项随机、开放标签、3 期、非劣效性研究。
Lancet. 2015 May 23;385(9982):2057-66. doi: 10.1016/S0140-6736(15)60936-9.
7
[A 45-fold liraglutide overdose did not cause hypoglycaemia].利拉鲁肽过量45倍未引发低血糖
Ugeskr Laeger. 2015 Jan 26;177(5):V11140595.
8
An accidental liraglutide overdose: case report.一例利拉鲁肽意外过量用药病例报告。
Libyan J Med. 2014 Jan 20;9(1):23055. doi: 10.3402/ljm.v9.23055. eCollection 2014.
9
10-fold liraglutide overdose over 7 months resulted only in minor side-effects.7个月内10倍剂量的利拉鲁肽过量服用仅导致轻微副作用。
J Clin Pharmacol. 2013 Jul;53(7):785-6. doi: 10.1002/jcph.94. Epub 2013 Jun 3.
10
Attempted suicide with liraglutide overdose did not induce hypoglycemia.过量使用利拉鲁肽自杀并未导致低血糖。
Diabetes Res Clin Pract. 2013 Jan;99(1):e3-4. doi: 10.1016/j.diabres.2012.10.017. Epub 2012 Nov 11.
Zotero 插件